MIPS - Quality Measures - Trastuzumab Received By Patients With AJCC Stage I (T1c) - III And HER2 Positive Breast Cancer Receiving Adjuvant Chemotherapy

Quality Measures
Category QUALITY
Description Proportion of female patients (aged 18 years and older) with AJCC stage I (T1c) - III, human epidermal growth factor receptor 2 (HER2) positive breast cancer receiving adjuvant chemotherapy who are also receiving trastuzumab
eMeasure ID
First Performance Year 2017
Last Performance Year
Metric Type Single Performance Rate
National Quality Strategy Domain ECR
Measure Type Process
eMeasure UUID
NQF eMeasure ID
NQF ID 1858
Is High Priority?
Is Inverse?
Overall Algorithm
Primary Steward American Society of Clinical Oncology
Submission Methods Registry
Eligibility Options
Performance Options
Is Risk Adjusted?
Vendor ID
Is Registry Measure?
Registry Measure Spec
Web Interface Measure Spec
Claims Measure Spec

Back to List